Innate Pharma SA
PAR:IPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Black Pearl SA
WSE:BPC
|
PL |
|
S
|
SPC Power Corp
XPHS:SPC
|
PH |
|
Lupaka Gold Corp
XTSX:LPK
|
CA |
|
Huabang Technology Holdings Ltd
HKEX:3638
|
HK |
|
A
|
Ashnoor Textile Mills Ltd
BSE:507872
|
IN |
|
New Wave Group AB
STO:NEWA B
|
SE |
|
A
|
AnGes Inc
OTC:AMGXF
|
JP |
|
Man Wah Holdings Ltd
HKEX:1999
|
HK |
|
Paid Inc
OTC:PAYD
|
US |
|
R
|
Royal Unibrew A/S
CSE:RBREW
|
DK |
|
T
|
Telsys Ltd
TASE:TLSY
|
IL |
|
S
|
Susco PCL
SET:SUSCO
|
TH |
|
I
|
Inbest Prime VI Inmuebles Socimi SA
MAD:YINB6
|
ES |
|
T
|
TMC Life Sciences Bhd
KLSE:TMCLIFE
|
MY |
|
Gungnir Resources Inc
XTSX:GUG
|
CA |
|
S
|
Sunview Group Bhd
KLSE:SUNVIEW
|
MY |
|
SBC Medical Group Holdings Inc
NASDAQ:SBC
|
US |
Innate Pharma SA
Research & Development
Innate Pharma SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innate Pharma SA
PAR:IPH
|
Research & Development
-€38.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Valneva SE
PAR:VLA
|
Research & Development
-€81.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Research & Development
-€44.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-14%
|
|
|
Inventiva SA
PAR:IVA
|
Research & Development
-€87m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Research & Development
-$113.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-13%
|
|
|
Abivax SA
PAR:ABVX
|
Research & Development
-€177.8m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
See Also
What is Innate Pharma SA's Research & Development?
Research & Development
-38.3m
EUR
Based on the financial report for Dec 31, 2025, Innate Pharma SA's Research & Development amounts to -38.3m EUR.
What is Innate Pharma SA's Research & Development growth rate?
Research & Development CAGR 10Y
-5%
Over the last year, the Research & Development growth was 20%. The average annual Research & Development growth rates for Innate Pharma SA have been 6% over the past three years , and -5% over the past ten years .
